Science

Developing Transformative Precision Immunotherapies

THE MOST COMPREHENSIVE T CELL TARGETING PLATFORM IN THE INDUSTRY

Patients diagnosed with solid cancers or autoimmune diseases often have limited and ineffective treatment options.

By understanding how the immune system recognizes, targets and destroys cancer cells, 3T’s technology is advancing the development of next-generation therapies that have the potential to be safer and more effective for these difficult-to-treat cancers.

Starting with a productive response from patients, we can identify shared targets and therapeutically active T cell receptors (TCR) and T cell receptor mimetics (TCRm). These novel targets and therapeutics can enable development of highly specific, safer and more effective cancer treatments.

ADDRESSING TODAY’S IMMUNOTHERAPY CHALLENGES

OUR PROPRIETARY, NOVEL TECHNOLOGY CALLED 3T-TRACE (T CELL RECEPTOR ANTIGEN AND CROSS-REACTIVITY ENGINE) ADDRESSES TWO MAJOR CHALLENGES IN CURRENT IMMUNOTHERAPY DEVELOPMENT.

Identifying Novel Targets

3T-TRACE identifies novel shared TCR targets of productive immune responses against solid tumors and other diseases.

Targeted Therapies

3T-TRACE is used to comprehensively screen TCR and TCRm molecules for specificity and off-target cross-reactivities, with the potential to create tumor-specific, safer therapies that can be delivered at higher doses.

3T-TRACE PLATFORM: WHERE SCIENCE MEETS AI

TCR AND TCRm MOLECULE PROFILING AND NOVEL TARGET IDENTIFICATION

3T-TRACE is a platform that combines high-diversity target libraries with active machine learning to identify novel targets and TCRs. This process identifies the most prevalent and immunogenic targets in solid tumors. Its expanded coverage and scale are applicable across all tumor types. Our machine learning identifies targets that are able to bind and activate T cell responses with high accuracy. Beyond cancer, we’re looking toward opportunities across multiple therapeutic areas, including autoimmune diseases.

HOW 3T-TRACE WORKS: Immune-guided target identification

Identify

We identify tumor-specific immune responses from patient samples, which is focused on identifying what the immune response sees in an anti-tumor responses.

Screen

We screen reactive TCRs and utilize 3T-TRACE, enabled by machine-learning algorithms, for high-throughput and comprehensive profiling of TCR specificity.

Validate

Specificity and cross-reactivity are validated by extensive characterization of the TCRs and their respective target biology.

MODALITIES

ENABLING MULTIPLE THERAPEUTIC MODALITIES ACROSS DISEASE AREAS

Technology enables target identification and therapeutic optimization

We’re looking toward opportunities across multiple therapeutic areas, including autoimmune diseases and viral infection. With our approach, we’re able to pursue multiple therapeutic modalities that are prioritized based on target biology.

TCRm bispecifics:

Best-in-class against known targets and first-in-class against novel targets

Peptide vaccine:

Potent and antigen-specific T cell modulators in oncology or autoimmunity

Novel TCR cell therapies:

Best-in-class TCR cell therapies against known targets and first-in-class against novel targets

CONTINUED INNOVATION

USING COMPUTATION TO ACCELERATE DRUG DISCOVERY AND DEVELOPMENT

3T Biosciences is a data-science driven company

Our core computational expertise includes data science, bioinformatics and engineering. These pillars allow us to make data-driven decisions to accelerate target discovery and therapeutic development. Our interdisciplinary team allows for short data cycles, and iteration between the experimental and computational team to predict, test, model and update our processes at multiple levels at scale.

Patient Biomarkers

Comprehensive profiling of patient immune responses and patient tumors allow us to identify tumor reactive T cell populations and features of patient immune health to identify the right patient populations.

3T-TRACE

Our synergistic platform uses high throughput screening and machine learning to identify novel targets and develop highly specific and potent therapeutics. Our advanced machine learning models allow us to iterate on our data to develop TCR and TCRm compounds and discover groundbreaking target biology.

Algorithm Development and High-Compute Infrastructure

Streamlined data processes and pipelines allow us to analyze and visualize our data for quick iteration, testing and modeling to accelerate our discoveries.